Skin Care and Treatments of Melbourne Dermatology - Clinique Medical Press Release

86,200+ expert documents for the skincare aficionado.

Home

Account Login/View Cart/Checkout

Perennial / Wisdoms

UV Exposure
Aging Skin and Mature Skin
Theories of Aging
Antioxidants
Sunscreens

Selected Skin Care

Avene
Dibi
Glytone
Heliocare
Kinerase
Kinerase PhotoFacials
Kinerase Pro+
La Roche Posay
MD Rx
Neostrata
OlosPrevage MD
RevaleSkin
Ti-Silc / Z-Silc
Tricomin
VitaMedica
Browse more brands.

Facial Skin Condition Treatments

Adult Acne
Dark Circles
Deep Wrinkles
Hyperpigmentation
Open Pores
Puffy Eyes
Rosacea

Body Skin Condition Treatments

Keratosis Pilaris

Skin Care Ingredients

Alpha Lipoic Acid
Arginine + Serine
Asiatic Acid
Blueberry
Caffeine
Capryloyl Salicylic Acid
Ceramides
Chlorogenic Acid
Chrysin
Coffee Berry
Hydrolyzed Hyaluronic Acid
Mexoryl
Pro-Xylane
Silymarin
Sodium Laureth Sulfate/Sulphate
Browse more ingredients.

Clinical Procedures and Topics

Aging Skin
French Skin Care
Idebenone
Klein Becker
Oxidative Stress
Perricone
Skin Structure
Stem Cells
Healthy Skin Barrier Function
Smoking
Sun Protection
Topical Vitamin C/Firming
Choices and Needs
Strivectin

Browse more clinical skincare topics.


Clinique Medical Press Release

ALLERGAN, INC., THE #1 GLOBAL MEDICAL AESTHETICS COMPANY, AND CLINIQUE, THE #1 PRESTIGE COSMETICS BRAND IN THE UNITED STATES, FORM STRATEGIC COLLABORATION TO DEVELOP NEW SKIN CARE LINE

(IRVINE, Calif. and NEW YORK, New York, January 24, 2008) — Allergan, Inc. (NYSE: AGN) and Clinique Laboratories, LLC, today announced a strategic collaboration which combines Clinique's expertise in product development and formulation with Allergan's leadership in the medical aesthetics market. The new skin care line, which will incorporate the Clinique brand name, will offer clinically proven skin care products to complement in-office aesthetic procedures. It will be sold exclusively in physicians' offices in the United States and is expected to launch in the fall of 2008.

Over the past ten years, non-surgical aesthetic procedures have increased nearly 750 percent, with consumers in the United States spending more than $12 billion on cosmetic procedures in 20061. The top five non-surgical aesthetic treatments in 2006, administered in the physician's office, included BOTOX® Cosmetic and hyaluronic acid dermal fillers such as JUVÉDERM®, laser hair removal, microdermabrasion and laser skin resurfacing. As more patients seek advice and treatments from aesthetic specialty physicians, there is a similar, growing trend of consumers purchasing skin care products in the physician's office. Allergan and Clinique expect to pioneer a new category of best-in-class skin care products sold exclusively in physicians' offices that will be Allergy Tested and 100% Fragrance Free.

"In collaboration with Clinique, our goal is to establish a leadership position in physician-dispensed skin care by offering a one-stop approach to specialized skin care products under a brand name that is trusted by consumers and backed by science on which physicians can rely," said David E.I. Pyott, Allergan's Chairman of the Board and Chief Executive Officer. "The collaboration combines Allergan's leadership in medical aesthetics and our deep understanding of the physician channel based on our Total Facial Rejuvenation portfolio - including BOTOX® Cosmetic, JUVÉDERM® and our skin care product line, with Clinique's history of formulating leading consumer skin care products guided by dermatologists. Together with our complementary strengths, we expect Clinique and Allergan to grow this market."

"Clinique's promise to our consumers has always been to create dermatologist guided, Allergy Tested, 100% Fragrance Free products that address skin care needs. Today we are entering a new phase of our relationship with the medical community," said Lynne Greene, Global President, Clinique Laboratories. "By joining forces with Allergan, the number one medical aesthetics company, we are now able to service consumers who are under the care of a physician with this completely new class of products."

"Clinique's rich dermatological heritage dates back 40 years," said William P. Lauder, President and Chief Executive Officer, The Estée Lauder Companies Inc. "This new skin care line, created in collaboration with Allergan, is the next generation of the expression of Clinique's unique position delivered through one of the fastest growing channels today, physicians' offices."

As part of the agreement, Clinique will be responsible for formulating, developing and manufacturing the new product line. Clinique will sell products to Allergan while Allergan will record sales to physicians and handle consumer and professional marketing and distribution. The agreement with Clinique will allow Allergan to expand the size of its current sales force dedicated to physician-dispensed skin care. Clinique and Allergan may also conduct clinical trials and work with the physician community to ensure the success of the new skin care line.

  1. # #

Important BOTOX® Cosmetic (Botulinum Toxin Type A) Information

BOTOX® Cosmetic is indicated for the temporary improvement in the appearance of moderate to severe frown lines between the brows in people 18 to 65 years of age.

Important BOTOX® Cosmetic (Botulinum Toxin Type A) Safety Information

Serious heart problems and serious allergic reactions have been reported rarely. If you think you are having an allergic reaction or other unusual symptoms, such as difficulty swallowing, speaking or breathing, call your doctor immediately. The most common side effects following injection include temporary eyelid droop and nausea. Localized pain, infection, inflammation, tenderness, swelling, redness and/or bleeding/bruising may be associated with the injection. Patients with certain neuromuscular disorders such as ALS, myasthenia gravis or Lambert-Eaton syndrome may be at increased risk of serious side effects. For full prescribing information, please visit www.botoxcosmetic.com.

Important JUVÉDERM® Safety Information

JUVÉDERM® is indicated for injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds), and is generally well tolerated. In clinical studies, adverse events were usually mild to moderate in nature, did not require intervention and lasted seven days or less. The most common side effects included temporary injection site reactions including redness, pain/tenderness, firmness, swelling, lumps and bumps and bruising. For complete patient safety and prescribing information, please visit www.Juvederm.com.

About Allergan, Inc. (NYSE: AGN)

Founded in 1950, Allergan, Inc., with headquarters in Irvine, California, is a multi-specialty health care company that discovers, develops and commercializes innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential — to see more clearly, move more freely, express themselves more fully. The Company employs more than 7,500 people worldwide and operates state-of-the-art R&D facilities and world-class manufacturing plants. In addition to its discovery-to-development research organization, Allergan has global marketing and sales capabilities with a presence in more than 100 countries.

About Clinique

Introduced in 1968, Clinique was the first ever dermatologist-created, prestige cosmetic brand. Clinique's mission has always been to provide the highest quality and most effective line of products to enhance every skin type and tone. The brand's customized approach and quality products ? all meticulously tested and carefully formulated with the latest science — have made Clinique one of the leading skin care authorities in the world. All makeup and skin care products are Allergy Tested and 100% Fragrance Free. Clinique offers products for men and women of all ages and ethnicities. Clinique is sold in more than 135 countries and territories, 17,000 sales locations and on www.clinique.com.

About the The Estée Lauder Companies Inc. (NYSE:EL)

Founded in 1946, The Estée Lauder Companies Inc. is one of the world's leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The Company's products are sold in over 135 countries and territories under well-recognized brand names, including Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, M•A•C, Bobbi Brown, Tommy Hilfiger, La Mer, Donna Karan, Aveda, Jo Malone, Bumble and bumble, Darphin, Michael Kors, American Beauty, Flirt!, Good Skin™, Grassroots, Sean John, Missoni, Daisy Fuentes, Tom Ford Beauty, Mustang, Coach and Ojon.

Allergan and The Estée Lauder Companies Inc. Forward-Looking Statements

This press release contains "forward-looking statements," including the statements by Mr. Pyott, Mr. Lauder and Ms. Greene and other statements regarding the market potential associated with the new product line. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Allergan's or The Estée Lauder Companies Inc.'s expectations and projections. Risks and uncertainties include, among other things, general industry and professional skin care channel conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; challenges related to product marketing, such as the unpredictability of market acceptance for new skin care products; inconsistency of treatment results among patients; the potential for product failures; potential difficulties in manufacturing new products; governmental laws and regulations affecting domestic and foreign operations and the ongoing success of the collaboration. Allergan and the The Estée Lauder Companies Inc. expressly disclaim any intent or obligation to update these forward-looking statements except as required to do so by law.

Additional information concerning these and other risk factors can be found in press releases issued by Allergan, as well as Allergan's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Allergan's 2006 Form 10-K and Allergan's Form 10-Q for the quarter ended September 28, 2007. Copies of Allergan's press releases and additional information about Allergan are available on the World Wide Web at www.allergan.com or you can contact the Allergan Investor Relations Department by calling (714) 246-4636.

Additional information concerning these and other risk factors can also be found in press releases issued by The Estée Lauder Companies Inc., as well as in its filings with the Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in The Estée Lauder Companies Inc. Form 10-K for the fiscal year ended June 30, 2007. Copies of The Estée Lauder Companies Inc. press releases, filings as well as additional information about the company, are available at www.elcompanies.com or you can contact The Estée Lauder Companies Inc. Investor Relations Department by calling (212) 572-4184.

Allergan Contacts

Jim Hindman (714) 246-4636 (investors)

Joann Bradley (714) 246-4766 (investors)

Emil Schultz (714) 246-4474 (investors)

Caroline Van Hove (714) 246-5134 (media)

Leslie Bryant (714) 246-6948 (media)

The Estée Lauder Companies Inc. Contacts

Dennis D'Andrea (212) 572-4384 (investors)

Clinique Laboratories Contacts

Sheila Munguia (212) 572-6810 (media)

ALLERGAN and BOTOX are registered trademarks of Allergan, Inc.

JUVÉDERM is a registered trademark of Allergan Industrie, SAS

The other trademarks in this press release are owned or licensed by subsidiaries of The Estée Lauder Companies Inc.

1 American Society for Aesthetic Plastic Surgery (ASAPS), 2006 Statistics on Cosmetic Surgery, www.surgery.org (January 24, 2008)

Related Skin Care Information, Products and Expert Discussions

Letter to Dennis Gay, CEO Basic Research regarding "Designer Steroids" such as Pedialean

Obagi Medical Products Presents In Vitro Data Showing Its Topical Vitamin C Serums Provide Greater Absorption and Stability Than a Leading Competitor

Body Shop Founder Annita Roddick Dies

Coming to Dermatology — Clinique + Allergan

Strivectin — Stretch Mark Topic Main Summary


Clinique Medical :

Clinique Medical Skin Care (Newly Available) : Clinique Medical Probiotic Cleanser : Clinique Medical Skin Conditioning Treatment : Clinique Medical Optimizing Treatment Cream : Clinique Medical Recovery Week Complex : Clinique Medical Daily SPF 38 : Clinique Medical Dry Spot Balm : Clinique Medical Optimizing Regimen : What Is Clinique Medical? : What’s So Different About Clinique Medical? : What Are The Benefits of Clinique Medical? : What Is In The Clinique Medical Product Lineup? : Who Is Clinique Medical For? : Where Can I Find Clinique Medical? : Before/After: Clinique Medical TCA Peel Treatment Study for Enhanced Outcomes : Comparison: Clinique Medical TCA Peel Treatment Study for Enhanced Outcomes : Before/After: Clinique Medical IPL Treatment Study for Enhanced Outcomes : Comparison: Clinique Medical IPL Treatment Study for Enhanced Outcomes : Clinique Medical Clinical Data: Healing Process : Clinique Medical TCA Peel Treatment Study for Enhanced Healing : Clinique Medical IPL Treatment Study for Enhanced Healing : The Importance of Pre & Post Proecedure Skin Care : About Post-Procedure Skin Care : About Ongoing Skin Maintenance : Clinique Medical Press Release :


New/Notable 2016

Open Pores — Treatment and Prevention

MD Rx Melbourne Dermatology Open Pores Overnight Solution

The Sun

Radiation

Mexoryl

Pentapeptides Ineffective

Asiaticoside vs. Madecassoside for Collagen Synthesis

La Roche-Posay Redermic

Valeant Pharmaceuticals

Rainbow

Telomerase

Azelaic Acid

Bisabolol

Avena Sativa

Panthenol

Aster Family of Plants

Green Tea (Camellia Sinensis) Extract

Polyphenols

Caffeine

Oxofulleram

Salicylic Acid

Capryloyl Salicylic Acid

Open Pores

Phytosphingosine

Glycerin

Idebenone

Ascorbyl Palmitate

Kojic Acid

Algorithm for Optimal Sustained Exfoliation: Glycolic Acid

Comparison of 33 Sunscreens